A Phase 3, Multinational, Randomized, Placebo-controlled Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation (REALM-DCM)
Latest Information Update: 20 Aug 2024
Price :
$35 *
At a glance
- Drugs Emprumapimod (Primary)
- Indications Dilated cardiomyopathy
- Focus Registrational; Therapeutic Use
- Acronyms REALM-DCM
- Sponsors Array BioPharma; Pfizer
- 01 Jul 2024 Primary endpoint (Change From Baseline in Six-Minute Walk Test (6 MWT) at Week 24) has not been met, according to Results published in the Circulation: Heart Failure.
- 01 Jul 2024 Results published in the Circulation: Heart Failure
- 04 Feb 2024 This trial has been discontinued in Italy according to European Clinical Trials Database record.